Home / Technology & Devices (page 5)

Technology & Devices

Amgen Invests $66 Million in Oxford Nanopore Technologies

THOUSAND OAKS, Calif. and OXFORD, England, Oct. 18, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Oxford Nanopore Technologies Ltd. today announced Amgen’s equity investment of £50 million ($66 million) in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology. Oxford Nanopore has developed and brought to market a proprietary sequencing technology that uses many nanopores …

Read More »

Exact Sciences Strengthens Pipeline Capabilities With Acquisition of Biomatrica, A Leading Provider of Biological Sample Preservation Technology

MADISON, Wis. and SAN DIEGO, Oct. 18, 2018 /PRNewswire/ — Exact Sciences Corp. (Nasdaq: EXAS) today announced the acquisition of Biomatrica, a leading developer, manufacturer and provider of sample preservation technology, including blood and saliva sample collection tubes, to the biotech industry. Biomatrica’s sample collection tubes, which contain proprietary, sample-stabilizing …

Read More »

Castle Biosciences’ Cutaneous Squamous Cell Carcinoma Prognostic Test Development Progress Highlighted at Dermatology Meeting

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced the presentation of data demonstrating progress in the development of a prognostic gene expression profile test for cutaneous squamous cell carcinoma (cSCC), one of the most common types of cancer. …

Read More »

Scripps Research Translational Institute Collaborates with Seqster To Bring Genetic Risk Scores With Health Data

SAN DIEGO, Oct. 16, 2018 /PRNewswire/ — Seqster, the leading consumer-centric health data management platform empowering employees, members, or patients to collect, own and share all of their health data, today announced a collaboration with Scripps Research Translational Institute (“SRTI”), creators of the MyGeneRank app at the 2018 American Society …

Read More »

Ionis Enters New Collaboration with Roche to Develop IONIS-FB-L Rx for Complement-Mediated Diseases

CARLSBAD, Calif., Oct. 10, 2018 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced a new collaboration with Roche to develop IONIS-FB-LRx for the treatment of complement-mediated diseases. This collaboration will leverage Ionis’ leadership in RNA-targeted therapeutics to develop IONIS-FB-LRx targeting Factor B (FB) for a broad range of diseases. The first indication the two companies will …

Read More »

Neovasc Reducer Granted Breakthrough Device Designation from the FDA

VANCOUVER, Oct. 10, 2018 /CNW/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the U.S. Food and Drug Administration …

Read More »

Veracyte Announces that New Data from Multiple Studies Demonstrate “Real World” Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) announced today that new findings from six studies reinforcing the “real world” performance of the next-generation Afirma Genomic Sequencing Classifier (GSC) and the Afirma Xpression Atlas in thyroid cancer diagnosis were presented at the 88th Annual Meeting of the American Thyroid Association (ATA). The …

Read More »

Kite and HiFiBiO Collaborate to Develop Technology for Potential Discovery of Neoantigen-Reactive T Cell Receptors for the Treatment of Cancer

SANTA MONICA, Calif. & HONG KONG–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), and HiFiBiO Therapeutics, a biotechnology company focused on the discovery of therapeutic antibodies through single B cell screening and analysis, announced the companies have entered into a research collaboration and license agreement to develop technology supporting the discovery …

Read More »

Dragonfly Collaborates with Merck to Develop Novel Drug Candidates for Solid Tumors Using Dragonfly’s TriNKET Platform

WALTHAM, Mass., Oct. 1, 2018 /PRNewswire/ — Dragonfly Therapeutics, Inc. (“Dragonfly”), today announced a strategic collaboration with Merck, known as MSD outside the United States and Canada, through a subsidiary, to discover, develop and commercialize innovative immunotherapies for patients with solid tumor cancers. The collaboration grants Merck the option to …

Read More »

FDA Authorizes Adaptive’s clonoSEQ Assay to Detect MRD in Patients with Multiple Myeloma and Acute Lymphoblastic Leukemia

SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies® announced today that the U.S. Food and Drug Administration (FDA) has granted De Novo designation for the clonoSEQ® Assay to detect and monitor minimal residual disease (MRD) in patients with multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (ALL) using DNA from a patient’s bone marrow sample. The clearance …

Read More »